Breakthrough T1D Closes First CRC, Sets 2027 Edition for Washington
Philadelphia – October 12, 2026 -- Breakthrough T1D, formerly JDRF, closed its inaugural Clinical & Research Congress after more than 80 sessions and scheduled the 2027 edition for Washington, D.C., October 15-17, 2027.
The congress ran October 9-11, 2026, in Philadelphia. It brought together clinicians, researchers, scientists, healthcare professionals, industry leaders, people with lived experience and community advocates.
Sessions span immunotherapies, islet cell therapies and AI-driven tools
The program covered endocrinology, discovery science and immunotherapies, and emerging technologies including AI and digital twins. It also addressed islet cell and disease-modifying therapies, and access to care for the type 1 diabetes (T1D) community.